ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
What the U.S. POINTER results mean for public health initiatives and the Alzheimer's Association.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Symptomatic treatment for Alzheimer disease: current evidence and future directions.Nature reviews. Neurology · 2026Review
- Older adults' views of passive smartphone monitoring for dementia risk: a multi-method analysis.Innovation in aging · 2026Article
- Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers.Clinical interventions in aging · 2026Review
- What the U.S. POINTER results mean for public health initiatives and the Alzheimer's Association.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Alzheimer's Association launched the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), a 2 year clinical trial to evaluate whether lifestyle or behavioral interventions that simultaneously target multiple risk factors protect cognitive function in > 2000 older adults (ages 60-79) at increased risk for cognitive decline. Top-line results from the study demonstrated that a structured, multi-domain lifestyle intervention significantly reduces cognitive decline compared to a self-guided approach over the 2 year interventions. U.S. POINTER positive trial results have far-reaching implications for public health, clinical care, and possibly dementia prevention strategies in the United States and the world. This perspective describes the implications and the Alzheimer's Association's commitment to creating the conditions that make this possible; activating individuals, communities, and organizations to take charge of and improve their brain health and creating conditions or environments for the success of implementation in communities. HIGHLIGHTS: A growing body of evidence suggests that lifestyle modifications may play a critical role in reducing the risk of cognitive decline and dementia. U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) positive trial results have far-reaching implications for public health, clinical care, and possibly dementia prevention strategies in the United States and the world. U.S. POINTER will significantly inform public health action on a multi-domain intervention for an at-risk population. Continued analysis of trial data, including biomarkers, along with insights from the Alzheimer's Association-funded Alumni Extension study, will offer additional insights on the impact of the trial intervention and provide valuable guidance on how best to adapt the intervention for diverse communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.